Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Harrer

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Reproduction and Fertility|May 1, 1973
Differential effects of oestrogen on the uptake of nucleic acid precursors by mouse blastocysts in vitroJ A Harrer, H H Lee
The British Journal of Dermatology|April 23, 2020
Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death-1 therapies and lessons learned from natalizumabA Harrer, R Lang, P Kölblinger
The Journal of Investigative Dermatology|February 1, 1986
Leu-3/T4 expression on epidermal Langerhans cells in normal and diseased skinV Groh, M Tani, A Harrer, et al.
Multiple Sclerosis and Related Disorders|January 8, 2021
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribineR F Radlberger, I Sakic, T Moser, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 4, 2011
Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodiesG Pilz, A Harrer, K Oppermann, et al.
Acta Neurologica Scandinavica|September 17, 2013
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?P Wipfler, A Harrer, G Pilz, et al.
Journal of Neurology|August 10, 2012
Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosisP Wipfler, A Heikkinen, A Harrer, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot studyH Hegen, M Guger, A Harrer, et al.
Journal of Neurology|July 25, 2021
Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse eventsC O Sullivan, F Zach, T Moser, et al.
Clinical and Experimental Immunology|April 25, 2013
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosisJ Sellner, W Koczi, A Harrer, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Reproduction and Fertility|May 1, 1973
Differential effects of oestrogen on the uptake of nucleic acid precursors by mouse blastocysts in vitroJ A Harrer, H H Lee
The British Journal of Dermatology|April 23, 2020
Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death-1 therapies and lessons learned from natalizumabA Harrer, R Lang, P Kölblinger
The Journal of Investigative Dermatology|February 1, 1986
Leu-3/T4 expression on epidermal Langerhans cells in normal and diseased skinV Groh, M Tani, A Harrer, et al.
Multiple Sclerosis and Related Disorders|January 8, 2021
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribineR F Radlberger, I Sakic, T Moser, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 4, 2011
Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodiesG Pilz, A Harrer, K Oppermann, et al.
Acta Neurologica Scandinavica|September 17, 2013
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?P Wipfler, A Harrer, G Pilz, et al.
Journal of Neurology|August 10, 2012
Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosisP Wipfler, A Heikkinen, A Harrer, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot studyH Hegen, M Guger, A Harrer, et al.
Journal of Neurology|July 25, 2021
Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse eventsC O Sullivan, F Zach, T Moser, et al.
Clinical and Experimental Immunology|April 25, 2013
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosisJ Sellner, W Koczi, A Harrer, et al.
Pageof 2